KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Short-term Investments (2022 - 2025)

Castle Biosciences' Short-term Investments history spans 4 years, with the latest figure at $182.8 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 5.39% year-over-year to $182.8 million; the TTM value through Dec 2025 reached $182.8 million, up 5.39%, while the annual FY2025 figure was $182.8 million, 5.39% up from the prior year.
  • Short-term Investments for Q4 2025 was $182.8 million at Castle Biosciences, down from $202.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $202.0 million in Q3 2025 and bottomed at $117.2 million in Q1 2023.
  • The 4-year median for Short-term Investments is $164.8 million (2024), against an average of $160.7 million.
  • The largest annual shift saw Short-term Investments grew 5.1% in 2023 before it soared 34.3% in 2024.
  • A 4-year view of Short-term Investments shows it stood at $135.7 million in 2022, then grew by 6.32% to $144.3 million in 2023, then increased by 20.22% to $173.4 million in 2024, then grew by 5.39% to $182.8 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Short-term Investments are $182.8 million (Q4 2025), $202.0 million (Q3 2025), and $193.7 million (Q2 2025).